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RESUMO 
O cancro colo-rectal (CCR) é um sério problema de saúde a nível mundial. Em 
Portugal, o CCR é a segunda causa de morte por cancro em ambos os sexos. A 
prostaglandina E2 (PGE2) é mediadora de uma grande variedade de efeitos 
fisiológicos e tem um papel chave na inflamação e no cancro. A concentração de 
PGE2 no microambiente do tumor depende do balanço entre a sua síntese, 
protagonizada pela ciclooxigenase-2 (COX-2), e a sua inativação catabólica pela 15-
prostaglandina desidrogenase (15-HPGD). A expressão aumentada de COX-2 e a 
sub-regulação de 15-PGDH têm sido observadas em CCR. O objetivo deste estudo foi 
avaliar a influência de polimorfismos dos genes PTGS2 e HPGD, que codificam a 
COX-2 e a 15-PGDH, respetivamente, numa população da região Norte de Portugal. 
Foi desenvolvido um estudo caso-controlo de base hospitalar envolvendo 798 
participantes: 254 pacientes com diagnóstico de CRC e 544 controlos sem evidência 
de cancro, recrutados no Instituto Português de Oncologia do Porto (IPO Porto). Os 
polimorfismos do gene PTGS2 (-1195A>G, -765G>C e 8473T>C) e os polimorfismos 
do gene HPGD (rs8752, rs2612656 e rs2555639) foram caracterizados recorrendo à 
técnica de discriminação alélica, por PCR em Tempo Real. O polimorfismo -1195A>G 
apresentou uma predisposição 2.04 vezes superior para o desenvolvimento de CCR. 
Numa análise estratificada, os homens e indivíduos ex-/fumadores, portadores do 
genótipo GG, apresentaram um risco aumentado para o desenvolvimento de CCR (OR 
3.10; 95% CI: 1.22-7.88; P=0,013 e OR 3.90; 95% CI: 1.17-12.96; P=0.019, 
respetivamente). Os portadores do genótipo -765CC apresentaram uma tendência 
protetora para o desenvolvimento de CCR (OR 0.62; 95% CI: 0.22-1.71; P=0.345). 
Similarmente, o polimorfismo rs2612656A>G associou-se a uma redução no risco para 
CCR (OR 0.62; 95% CI: 0.43-0.90; P=0.011), que foi mais evidente em mulheres, 
indivíduos não fumadores  e obesos portadores do genótipo AG (OR 0.38; 95% CI: 
0.19-0.76; P=0.005, OR 0.53; 95% CI: 0.28-0.97; P=0.039 e OR 0.39; 95% CI: 0.15-
0.97; P=0.039, respetivamente). Relativamente ao polimorfismo rs8752C>T, 
portadores do genótipo CC, apresentaram um aumento de 40% de risco para o 
desenvolvimento de CCR (OR 1.41; 95% CI: 0.90-2.22; P=0.133), o qual atinge 
valores significativos em indivíduos com idade superior a 59 anos (OR 1.94; 95% CI: 
1.04-3.61; P=0.035). Podemos concluir que os polimorfismos -1195A>G e -765G>C do 
gene PTGS2 e rs2612656 e rs8752 do gene HPGH parecem influenciar a 
suscetibilidade genética para CRC. Este é o primeiro estudo a avaliar a associação 
entre polimorfismos no gene HPGD e a suscetibilidade para CCR numa população 
portuguesa. Os nossos resultados reforçam a importância da via da PGE2 na 
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carcinogénese colo-rectal mostrando que uma melhor compreensão da etiologia do 
CCR pode permitir a caracterização de sub-grupos de indivíduos com maior risco, os 
quais poderão beneficiar de estratégias quimiopreventivas. 
 
Palavras-chave: Cancro colo-rectal; PTGS2; HPGD; Polimorfismo 
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ABSTRACT 
Colorectal cancer (CRC) is a major health problem worldwide. In Portugal, CRC is the 
second most common cause of cancer-related death in both genders. Prostaglandin E2 
(PGE2) mediates an extensive range of physiological effects and has a key role in 
inflammation and cancer. The concentration of PGE2 in the tumor microenvironment 
depends on the balance between its synthesis by cyclooxygenase-2 (COX-2) and its 
catabolic inactivation by 15-hydroxyprostaglandin dehydrogenase (15-PGDH). 
Enhanced expression of COX-2 and down-regulation of 15-PGDH has been observed 
in CRC. The aim of this study was to evaluate the influence of PTGS2 and HPGD 
polymorphisms in a population from the Northern region of Portugal. We conducted a 
hospital-based case-control study with 798 participants: 254 histologically confirmed 
CRC patients and 544 cancer-free controls recruited at Portuguese Institute of 
Oncology of Porto (IPO Porto). The PTGS2 polymorphisms (-1195A>G, -765G>C and 
8473T>C) and the HPGD polymorphisms (rs8752, rs2612656 and rs2555639) were 
characterized by allelic discrimination with Real-Time PCR. The -1195A>G 
polymorphism was associated to 2.04-fold increased predisposition to CRC onset. In a 
stratified analysis, men and ever-smokers carrying -1195GG genotype had an 
increased risk for CRC development (OR 3.10; 95%CI: 1.22-7.88; P=0.013 and OR 
3.90; 95%CI: 1.17-12.96; P=0.019, respectively). The -765G>C polymorphism was 
associated with a protective trend for CC homozygous (OR 0.62; 95% CI 0.22-1.71; 
P=0.345). The rs2612656A>G polymorphism was significantly associated with a 
protective role for CRC (OR: 0.62; 95% CI: 0.43-0.90; P= 0.011) and a measurable 
interaction was detected between the AG genotype and gender (OR 0.38; 95% CI: 
0.19–0.76; P=0.005 in females) or smoking habits (OR 0.53; 95% CI: 0.28–0.97; 
P=0.039 in never-smokers); more interestingly, the protective role seemed to be 
modulated by a high BMI also in individuals carrying the AG genotype (OR 0.39; 95% 
CI: 0.15–0.97; P=0.039 in individuals with BMI ≥30). For the rs8752C>T polymorphism, 
individuals carrying the CC genotype were associated with a nonsignificant 40% 
increase in risk of CRC (OR 1.41; 95% CI: 0.90-2.22; P=0.133) that reaches 
significance level when we assessed possible gene-environment interactions (OR 1.94; 
95% CI: 1.04-3.61; P=0.035 in individuals over age 59). These findings revealed that -
1195A>G and -765G>C PTGS2 polymorphisms and rs2612656 and rs8752 HPGH 
polymorphisms appear to modulate the genetic susceptibility to CRC onset. This is the 
first study to evaluate the association between HPGD polymorphisms and CRC 
susceptibility in a Portuguese population. Our results support the importance of the 
PGE2 pathway in CR carcinogenesis showing that a better understanding on CRC 
FCUP 
Role of genetic polymorphisms in PTGS2 and HPGD in colorectal cancer development 
 
 
 VI  
etiology might allow the characterization of sub-groups of individuals at higher risk who 
will most benefit from personalized chemopreventive strategies. 
 
Keywords: Colorectal Cancer; PTGS2; HPGD; Polymorphism 
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1. Cancer 
Cancer is the leading cause of death in developed countries and has a profound impact 
on patients, family and society and is probably the most feared diseases in the 
population. In 2008, it was estimated that 12.6 million people were diagnosed with 
cancer across the world and 7.6 million cancer deaths occurred worldwide [1]. 
According to Bray et al. there will be almost 22.2 million new cases diagnosed annually 
worldwide by 2030 [2]. 
Cancer is a term used to describe a mass of cells that are abnormally growing without 
control and are able to invade other tissues. The carcinogenesis process is 
characterized by the evolution of normal cells into neoplastic cells by the acquisition of 
six biological capabilities: sustaining proliferative signaling, escape growth 
suppressors, cell death, angiogenesis, invasion and metastasis [3] - figure 1. Cancer is 
considering a multifactorial disease where both genetic and environmental factors are 
part of a multistep process [4]. 
 
Figure 1. The Hallmarks of Cancer – six core and two emerging - and Enabling Characteristics (adapted from Hanahan 
and Weinberg, 2011) [3]. 
 
Of all carcinogenic agents, there are many, which are well known to increase the risk of 
cancer development including tobacco, radiation, lack of physical activity, obesity, 
environmental pollutants and infection agents [5]. These agents can directly damage 
genes or combine with existing genetic determinants leading to cell deregulation and 
the development of neoplastic cells [6]. 
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1.1 Colorectal cancer epidemiology 
Colorectal cancer (CRC) is a serious health problem with an annual incidence of 
1.235,108 cases and a mortality rate of 609,051 cases per year [1]. It is the third most 
common malignancy and the fourth most common cancer cause of death worldwide, as 
can be seen in Figure 2.  
 
Figure 2. Estimated age-standardised incidence and mortality rates in both genders worldwide [1]. 
 
The worldwide distribution of CRC is very heterogeneous and it is more common in 
developed countries than in developing ones. In fact, United States of America, 
Canada, Western Europe, Australia, Japan and New Zealand are among the countries 
with highest incidence rates [1] - figure 3. According to the World Health Organization 
(WHO), CRC is the most common malignant tumor in the European Union [7] with 
about 4% of men and 3% of women to be at risk of developing CRC until age 75 [8].  
 
Figure 3. Incidence distribution of colorectal cancer worldwide in 2008 (per 100.000) [1].
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In Portugal, CRC incidence is of 6,952 cases and mortality of 3,691 cases per year [1]. 
According to published data, mortality has significantly increased over the last few 
decades and still is the second most common cause of cancer-related deaths in 
women (after breast cancer) and in men (after lung cancer) [1]. According to Registo 
Oncológico Regional do Norte (RORENO) [9], the total number of new patients seen at 
the IPO in Oporto during the year of 2010 was 10241. Of these, 7050 (69%) were 
diagnosed with malignant tumors including 433 from colon and 396 from rectum. 
Surviving CRC highly depends on the stage of the disease when it is diagnosed. 
Usually people with cancers that are detected at the localized stage had a 90% 5-year 
survival rate while only 10% of the people diagnosed for distant metastatic cancer has 
the chance of surviving [10,11]. In general, earlier stages diagnoses increase the 
chance of survival. Nevertheless, in Europe, CRC is the third leading cause of cancer 
death with 212,219 deaths in 2008 [1]. 
Hence, as CRC incidence is expected to increase in the near future as a result of 
population aging and increased life expectancy, some regions in Europe, where 
preventive strategies, early screening and treatment were adopted, are succeeding in 
reducing the number of cancer deaths [12-14]. 
 
1.2 CRC etiology and risk factors   
In the vast majority of cases, CRC is sporadic (with no background of a family history of 
the disease), nevertheless there are genetic hereditary syndromes such as familial 
adenomatous polyposis (FAP), which accounts for approximately 1% of cases, and 
hereditary non polyposis colorectal cancer (HNPCC), which accounts for 5% to 10% of 
cases [15,16]. 
Sporadic CRC is considered to be an environmental disease since it is associated with 
lifestyle factors that contribute to increased risk of CRC. Some of the evidence of 
environmental risk factors comes from studies with migrants. The incidence rate of 
CRC in migrants tends to increased when they travel from low-risk to high-risk 
countries [17,18]. 
In fact, CRC is a multistep/multifactorial disease on which several risk factors are 
associated with its development. Generally, we may divide risk factors in two distinct 
categories: 1) modifiable factors (tobacco, lack of physical activity, obesity, etc.) and 2) 
non-modifiable factors (age, race, family history) [19,20]. 
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Age is consistently considered a major risk factor for the development of sporadic 
CRCs since its incidence begins to rise between the age of 40 and 50 years. In fact, 
age-specific incidence rates increase significantly in each subsequent decade 
thereafter [19,20]. Other non-modifiable factors include Inflammatory Bowel Disease 
(IBD) [21], personal or family history of CRC or colorectal polyps [22], and a genetic 
syndrome such as FAP or HNPCC [23,24]. 
The International Agency for Research on Cancer (IARC) has been showing that there 
is sufficient evidence to conclude that tobacco is highly associated with CRC 
development [25]. Several studies have shown that carcinogens found in tobacco 
amplified cancer growth in the colon and rectum and the risk of being diagnosed with 
this type of cancer [26,27]. 
Other factor risk includes diet and physical activity. High levels of physical activity 
decrease the risk of colon cancer by almost 50% [28] and also contributes to decrease 
obesity, which is another factor associated with CRC [29]. Several studies have found 
that high consumption of red meat and low fruit and vegetables intake increases the 
risk of CRC [29-33]. Moreover, CRC has been linked to alcohol consumption. 
Individuals who consume less than one drink per day have lower risk of CCR than 
those who have a lifetime average of 2 to 4 alcoholic drinks per day [34]. 
Despite the importance of early detection, there are many studies suggesting that 
modifying lifestyle would reduce significantly CRC incidence [35-37]. 
 
1.3 CRC biopathology and carcinogenesis 
CRC includes all neoplastic malignant lesions that are in the large bowel (cecum, 
ascending/transverse/descending colon and sigmoid), rectum and anal canal [38]. 
CRCs develop from apparently normal mucosa into a benign precursor stage, the 
premalignant polyp, and can progress to invasive disease [39]. The collaboration 
among surgeons, gastroenterologists, oncologists, pathologists, geneticists and 
molecular scientists allowed us to understand the dynamic molecular and 
histopathological changes that occur in CCR. 
The development of CRC is often very silent, since in the majority of cases it is 
asymptomatic. Nevertheless, in symptomatic cases, there are some differences 
regarding the signs and symptoms depending on the localization of the tumors: in the 
ascending colon it is frequent to find anemia; while in the descending/sigmoid colon it is  
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frequent to find obstipation and hematochezia [40,41]. In fact these are the reasons 
why so frequently CRC is found in advanced stages. If diagnosed early, CRC has a 
cure rate of 90%, while if diagnosed in late stages, this percentage decreases up to 5% 
in metastatic cases [42]. Hence, the success rate is depending on the ability to detect 
early stage cases.  
The advances in genetic and molecular biology of cancer led to a rapid knowledge of 
gastrointestinal cancers pathogenesis, nevertheless it took about a decade to 
demonstrate all the molecular mechanisms that allow the transformation from normal 
mucosa to adenocarcinoma [43] - figure 4. CRC carcinogenesis is known to develop 
according to a cascade named “adenoma-carcinoma sequence” [45]. This pathogenic 
pathway occurs through a number of morphologically identifiable stages: colon 
epithelial proliferation, small adenomas formation, gradual increase of adenomas and 
their degree and carcinoma. Several authors have described this pathway as an 
evolution of premalignant adenomatous polyps. There are evidences that support this 
theory: 1) Patients who have undergone resection of adenomatous polyps are at 
increased risk for subsequent development of CRC [46]; 2) Adenomatous polyps occur 
in younger persons than do carcinomas [47]; 3) Colonoscopic polypectomy reduces the 
expected incidence of CRC [48] and 4) Adenomas are present in more than 30% of 
persons older than 50 years and their prevalence increases with age [49].  
 
Figure 4. CRC carcinogenesis (Kutz H et al., 2004) [44].
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This cascade is a result of genetic mutations, along with environmental influences, 
causing inactivation or promotion of specific genes known as tumor suppressor and 
tumor promoter genes [50]. This “adenoma-carcinoma sequence” spans for over 10-15 
years and therefore provides excellent opportunities for CRC prevention [45]. Early 
screening, treatment and follow-up of individuals previously diagnosed with adenomas 
(who have high risk of recurrence and develop cancer) is the keystone for CRC 
prevention and the best approach for CRC-associated mortality reduction. Thus, 
improved CRC screening guidelines and preventive strategies are still required to 
reduce the burden of this cancer.  
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2. Inflammation and CRC 
One of the highlighted fields of interest in the development and progression of CRC 
has been inflammation, which is considered to have a crucial role in cancer initiation 
[51,52]. In fact, literature reports the evidence that CRC is more frequently found in 
patients with IBD [53]. And despite patients with IBD represent a small part of CRC 
cases (1–2%), these patients are among those at greatest risk. In addiction it has been 
described that patients with prolonged (>30 years) and extensive colitis, have an 
increased risk of CRC development [54]. It is also known that chronic inflammation 
promotes carcinogenesis by inducing gene mutations, inhibiting apoptosis, or 
stimulating angiogenesis and cell proliferation [55]. On the other side, many authors 
have been supporting that the use of non-steroidal anti-inflammatory drugs (NSAIDs) 
reduces the incidence and mortality of several cancers, including CCR [56]. 
 
2.1 COX and NSAIDs 
Cyclooxygenases (COXs), also known as prostaglandin endoperoxide synthases 
(PTGS), are rate-limiting enzymes that convert free arachidonic acid into several 
prostaglandins, namely prostaglandin E2 (PGE2) [57], inducing the immune response 
via the “inflammation pathway” [58] - figure 5. 
 
 
Figure 5. Arachidonic acid cascade pathway (http://en.wikipedia.org/) [59]. 
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This enzyme has at least two isoforms identified usually referred as COX-1 and COX-2 
[60]. COX-1 is constitutively expressed in a wide range of organs and responsible for 
tissue homeostasis; COX-2, is almost undetectable under normal physiological 
conditions but readily induced in response to tumor promoters, growth factors and 
inflammatory cytokines [60,61]. In fact, COX-2 was shown to be up-regulated in 40-
50% of adenomas and 85% of CRC and is considered a key and early oncogenic event 
in colorectal carcinogenesis [60-62].  
The most abundant PG in colorectal tumors is the COX-2-derived PGE2, which 
stimulates cell proliferation, invasiveness and migration, enhances angiogenesis, 
inhibits apoptosis and modulates immunosuppression [63]. PGE2 promotes 
carcinogenesis and cancer progression due to its interference with the hallmarks of 
cancer development, including inflammation [64]. The presence of PGE2 in the 
microenvironment seems to favor tumor progression but a better understanding of 
PGE2 synthesis pathway in colorectal carcinogenesis is necessary to help target 
potential measures of cancer prevention and to allow the identification of higher risk 
individuals. The steady-state level of PGE2 is maintained in the tumor 
microenvironment by a balance between biosynthesis and degradation. As PGE2 
levels are important for tumor development, the ability to control its expression is 
necessary to suppress tumor growth. The 15-hydroxyprostaglandin dehydrogenase 
(15-PGDH) is an enzyme, encoded by the hydroxyprostaglandin dehydrogenase 
(HPGD) gene that converts PGE2 into 15-keto-prostaglandin, eventually leading to the 
inactivation of PGE2 [64-67]. Therefore, 15-PGDH is considered to have tumor 
suppressor activity in human gastrointestinal malignancies by counteracting COX-2 
actions [67,68]. In fact, 15-PGDH is normally expressed in gastrointestinal mucosa and 
has been shown to be down-regulated in CRC, thereby providing a potential 
mechanism for local accumulation of PGE2 and consequently favor tumor development 
[69]. These findings and the fact that PGDH expression is reduced in inflammatory 
bowel disease [70], a condition associated with markedly increased CRC risk, increase 
the oncogenic potential of the PGs synthesis pathway. 
Therefore, to prevent CR carcinogenesis is important to control inflammation and many 
have suggested that the use of NSAIDs could benefit patients. NSAIDs are mainly 
responsible for the inactivation of COX enzymes [71], and clinical trials among either 
NSAIDs or selective COX-2 inhibitors have been revealing promissory results in 
colorectal adenoma prevention. Several studies suggest that the number of adenomas 
may decrease by almost 50% [72-77].  
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3. Genetic predisposition for CRC development 
It is known that genetic predisposition has a key role in CRC development. An 
extensive analysis of twins from Sweden, Denmark, and Finland demonstrated that 
heritability contributes to 35% of all CRC cases [78]. In addition, almost 20% of all 
patients with CRC have a positive familial history [79] whereas only 5 to 10% fulfills the 
criteria for hereditary colorectal cancer, what could suggest the implication of low-
penetrance alleles for the remaining familiarity [80]. Hence, there is a significant 
importance of low-penetration risk factors for the development of CRC. 
Polymorphisms are common DNA genetic alterations present in at least 1% of the 
general population [81] that have been associated with differential susceptibility to the 
development of several diseases, including cancer. Single Nucleotide Polymorphisms 
(SNPs) are the simplest type of polymorphism and result from a single base mutation, 
which substitutes one nucleotide for another [82]. Since SNPs are inherited from one 
generation to the next, less mutable and have high frequency in the genome, they are 
largely used in the genetic dissection of diseases such as cancer [82].  
Nowadays several epidemiological and molecular studies are focusing on SNPs and 
their ability to modulate the risk of various cancer and some of them have concluded 
that various gene polymorphisms can affect the risk of cancer development in almost 
all the populations around the world [83,84]. 
The number of studies attempting to determine which SNPs are likely to be implicated 
in CRC carcinogenesis, either alone or by interactions with environmental factors, 
continues to increase. Knowing that chronic inflammation is implicated in the etiology of 
CRC, our group has been developing molecular epidemiology studies on genes that 
are strongly related with inflammation, in particularly, genes that influence the levels of 
PGE2 in the tumor microenvironment, such as PTGS2 and HPGD. 
 
3.1 Genetic variability in PTGS2 gene 
COX-2 is an enzyme encoded by the PTGS2 gene, which spans about 8.3 kb on 
chromosome 1q25.2-q25.3 and has 10 exons and 9 introns [85]. Transcriptional 
regulation has been shown to be a major mechanism in COX-2 expression [86]. The 
study of the PTGS2 promoter region has recognized several potential transcription 
regulatory elements, which may play a crucial role in the regulation of PTGS2 
transcription [87,88]. In addition to variations in the promoter region, sites in the 3’- 
untranslated region (3’-UTR) of the gene may also be involved in CRC development. 
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This region is extremely important because it influences the mRNA transcripts ‘stability 
and ultimately regulates prostaglandins production [89-91]. 
PTGS2 is a highly polymorphic gene, which contains more than 500 polymorphisms 
described so far. However, only a few have been associated with gastrointestinal 
tumors development [92-94].  
 
3.1.1 The -1195A>G polymorphism 
The -1195A>G polymorphism is located in the promoter region of PTGS2, 
characterized by a adenine (A) to guanine (G) transition at position -1195 from exon 1. 
According to Tang et al. [95] a significant variation was observed in the frequency of 
this polymorphism. The -1195A allele frequency in Asian populations is significantly 
lower (46%) than that in European (75%) and that in mixed ethnicity (82%) [95].  
So far, functional studies have shown that the -1195A>G polymorphism regulates 
PTGS2 transcription activity and COX-2 expression, by creating different recognition 
binding sites for nuclear proteins [96,97]. 
In a previous observational study developed by Zhang et al. [96] in a Chinese 
population, the -1195AA genotype was associated with increased risk of esophageal 
squamous cell carcinoma. In addition, the AA genotype was further associated with a 
higher genetic predisposition for the development of gastric and colorectal 
adenocarcinomas in Asiatic populations [98,99]. However, another case control study 
reported a decreased risk for CR adenoma onset associated with 1195AA genotype 
[100], which, although rather unexpected, was further supported by a study involving 
FAP patients reporting an increased risk association between -1195GG genotype and 
CRC onset [101]. Similarly, our group in a preliminary study demonstrated that 
individuals carrying at least one G allele had a higher genetic predisposition to 
developed CRC [102]. These contradictory associations seem to suggest that the 
behavior of this polymorphism can be modulated by other factors. 
 
3.1.2 The -765G>C polymorphism  
-765G>C is the most extensively studied polymorphism on PTGS2, especially in 
gastrointestinal cancers. It is located in the promoter region of PTGS2, characterized 
by a guanine (G) to cytosine (C) transition at position -765 (-765G>C) from exon 1 
[103]. The -765C allele is quite frequent in Caucasians and African Americans, with 
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frequencies of 25-50% in different countries while the variant allele is fairly rare in 
Asians [104]. This polymorphism appears to disrupt the recognition binding site for 
Stimulatory protein 1 (Sp1), which is considered to be a positive activator of 
transcription, leading to a 30% reduction of the PTGS2 promoter activity in vitro [103]. 
In contrast, -765G>C also creates a binding element for the E2F transcription factor, a 
cyclin-dependent regulator of expression of several genes [96,98], that might 
eventually lead to an increased prostaglandin biosynthesis which in chronic conditions 
induces cancer development [104]. 
In Italy, it was observed that individuals carrying the -765C allele had lower risks of 
myocardial infarction and ischemic stroke [105], and in Spain it was associated with 
lower COX-2 expression and reduced atherosclerosis in patients with 
hypercholesterolemia [106]. In contrast, our group considered the -765C allele an 
increased susceptibility marker for gastric adenocarcinoma development in patients 
with atrophy or intestinal metaplasia [107]. 
Several studies have investigated the role of -765G>C polymorphism in CRC or CR 
adenomas onset, but their results have been inconsistent. One study found no 
association between this polymorphism and CRC [108] or CR adenomas [109]. 
Another study involving a population of Japanese men showed a decreased risk of CR 
adenomas linked with the GC genotype [100] while others associated this genotype 
with a significant increased risk of CRC [110]. Ulrich et al. related the CC genotype with 
decreased risk of CR adenomas among individuals who did not take aspirin or other 
NSAIDs [111]. More recently, it was observed an increased risk for CRC development 
in individuals carrying the GG genotype in a Dutch population [112].  
 
3.1.3 The 8473T>C polymorphisms 
The 8473T>C polymorphism is located in the 3’-UTR region of PTGS2, characterized 
by a thymine (T) to cytosine (C) transition at position 8473 (8473T>C). Several studies 
revealed that the 8473C allele frequency in Caucasians is approximately 30% 
[92,100,108]. The 3’-UTR region contains highly conserved adenosine and uridine rich 
elements, which are known as AU rich elements [89]. This motif is known to regulate 
mRNA stability and degradation of several other early intermediate genes encoding 
inflammatory mediators and also enhance the mRNA transcripts’ stability leading to an 
increased prostaglandins production [113-117]. 
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Some studies that investigated the PTGS2 8473T>C polymorphism, found the C 
variant allele to be associated with increased risk for non-small cell lung, breast and 
colorectal cancers [108,115,118]. In contrast to these results, other studies reported a 
protective effect of the same genetic polymorphism against lung and gastric cancers 
[92,119,120]. However, there are some studies that establish no association between 
this polymorphism and CRC cancer [102,121,122]. Regarding to CR adenomas, one 
study found the TC genotype to be associated with 47% increased risk [123] while 
other associated it with 31% increased risk [114]. In contrast, Gong and coworkers 
[109] reported evidence that individuals with the COX-2 8473C variant allele who also 
regularly take NSAIDs may be at low risk for CR adenomas.  
These results may show the importance of study molecules involved in the arachidonic 
acid cascade and their implications in the etiology of several types of cancer. 
 
3.2 Genetic variability in HPGD gene 
15-PGDH is an enzyme encoded by the HPGD gene, which spans about 31 kb on 
chromosome 4q34-q35, contains 7 exons, 6 introns [124] and several regions within 
the 5-ﬂanking region with clustered putative transcription factor-binding sites [125].  
As well as PTGS2, HPGD is also a highly polymorphic gene with more than 700 
polymorphisms described. However, only in the last few years some interest has been 
aroused in the role of genetic variations in HPGD gene. In 2008, recessive mutations in 
HPGD were identified as responsible for primary hypertrophic osteoarthropathy [126]. 
These mutations lead to a chronic increase in PGE2 levels, which is known to be 
implicated in colorectal cancer [127,128]. Besides that, it has been reported that this 
gene can act as tumor suppressor in different cancers, such as bladder, breast, gastric, 
lung and colorectal [129-138].  
Only five studies have been conducted to evaluate the implication of polymorphisms in 
this gene in colorectal carcinogenesis [139-143]. Despite the lack of functional data 
describing polymorphisms in HPGD gene on development of CRC, we were able to 
selected three polymorphisms that were previously associated with colorectal lesions 
[139-141]. The rs8752T>C polymorphism is located in the 3’-UTR region of HPGD, 
characterized by a thymine (T) to cytosine (C) transition from exon 7. The 
rs2612656A>G polymorphism is characterized by a adenine (A) to guanine (G) 
transition in the intron between exons 4 and 5. Both SNPs were previously associated 
with a higher CRC risk [141]. Quite contrary to these results, Frank et al. [139] found 
rs8752 to be significantly associated with decreased CRC risk both among individuals 
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with a BMI<30 and among smokers. The rs2555639T>C is located in the 5’ UTR region 
of HPGD, characterized by a thymine (T) to cytosine (C) transition. And a recent study 
suggests that the rs2555639 T allele is associated with an increased risk of colorectal 
cancer, and that carriers of this risk allele exhibit lower expression of 15-PGDH in the 
colon [140].  
Since the information about HPGD polymorphisms is scarce and genotyping all the 
SNPs present in this gene were practically infeasible, a tag-SNPs approach was 
chosen in four studies [139,141-143]. With this approach it is possible to sequence only 
a small number of SNPs, called tag SNPs, and then infer the rest of SNPs (or certain 
suspicious SNPs) based on the sequenced tag SNPs. So, the rs8752T>C and 
rs2612656A>G polymorphisms represent a haplotype block. The identification and 
analysis of haplotypes is expected to play a key role in disease association studies 
[144].  
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It is plausible, that some genetic polymorphisms in PGE2 pathway genes might have 
functional repercussion on protein expression/function and expectably in PGE-2 levels 
contributing to colorectal carcinogenesis. However, more studies are needed to clarify 
the heterogeneity observed between published studies and to allow us the recognition 
of individuals at higher risk for CRC that may beneficiate from optimized preventive 
strategies.  
The aim of this study was to evaluate the influence of the -1195A>G (rs689466), -
765G>C (rs20417) and 8473T>C (rs5275) PTGS2 polymorphisms and rs8752T>C, 
rs2612656A>G and rs2555639T>C HPGD polymorphisms on the development of CRC 
in a population from the Northern region of Portugal. 
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1. Study design 
We have designed a retrospective case-control hospital-based study gathering patients 
with CRC and healthy controls. 
 
2. Study population 
This study included 798 participants: 254 histologically confirmed CRC patients and 
544 cancer-free controls, from the northern region of Portugal and recruited at the 
Portuguese Institute of Oncology of Porto (IPO Porto). 
Written informed consent was obtained from all recruited participants before their 
inclusion in the study, according to the Declaration of Helsinki. This research project 
was approved by the Ethics Committee of the IPO Porto (ref. 0084/08) and Comissão 
Nacional de Protecção de Dados (ref. 6619/2011) that is the Portuguese Data 
Protection Authority. 
 
2.1. Control Group 
In this group, individuals between 50 and 75 years of age, without any clinical evidence 
of CRC or other oncologic malignancy were randomly recruited from the blood donor’s 
service at IPO between July 2005 and February 2008. 
 
2.2. CRC Patients Group 
Patients with histopathologically confirmed CRC newly diagnosed between January 
2002 and September 2007 were enrolled in this study. These patients were selected 
from a colonoscopy database from the Gastroenterology Department, aged 50–75 
years, without previous history of inflammatory bowel disease or hereditary syndromes 
and whom were scheduled for a follow-up consult at Serviço de Gastrenterologia or 
Unidade de Digestivos at IPO Porto during March and May 2008 (n=387 cases).  
Two-hundred and fifty four CRC patients were included out of the 387 expected to be 
recruited. During the recruitment or afterwards by telephone interview patients were 
asked to recall their lifestyle habits (smoking behavior, BMI, etc) in the previous year of 
CRC diagnosis. Medical records were reviewed to extract the clinicopathological 
variables (stage, tumor grade, presence of synchronous and metachronous lesions) 
and to exclude misclassification bias.  
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3. Sample collection and biological processing 
Blood samples were collected using standard venipuncture technique with EDTA 
containing tubes. DNA was extracted from peripheral blood leukocytes using the 
QIAamp® DNA Blood Mini Kit (Qiagen, Madrid, Spain), following the manufacturer’s 
instructions  
For patients unable to provide a blood sample, the DNA was extracted from formalin 
fixed paraffin embedded (FFPE) blocks from the Pathology Department of our institute. 
Two to four 10µm thickness section were used in each extraction depending on the 
size of tissue area (1.5-3 cm2). Briefly, the CRC tissue specimens from each glass slide 
were scraped, using a clean razor blade, into a 1,5-ml microcentrifuge tube. The 
samples were deparaffinised in xylene for 10 minutes, at room temperature, followed 
by centrifugation at 14.000g-16.000g for 3 minutes. The tissue pellets were then 
rehydrated with 1ml of absolute ethanol, followed by centrifugation at 14.000g-16.000g 
for 3 minutes and the supernatant was discarded. This step was repeated twice. Then, 
the tube was maintained open for 15 minutes to evaporate any remaining ethanol. 
Further steps of DNA isolation were performed using the GRS Genomic DNA Kit – 
Tissue, in accordance with the manufacturer’s protocol (GRiSP, Porto, Portugal).  
DNA was quantified using the NanoDrop 1000 Spectrophotometer (Thermo Fisher 
Scientific, Wilmington, DE, USA) and stored at -20°C until genotype examination. The 
DNA quality was determined by measuring the optical density (OD) 260/280 ratio. 
 
4. Validation of DNA genotyping extracted from FFPE samples 
To assess whether DNA isolated from FFPE sections is reliable for retrospective 
genotyping we compared the genotypes of 20 somatic DNAs extracted from FFPE 
specimens to germline DNAs isolated from fresh peripheral blood from the same 
patients. The genotypes were highly concordant (100%). 
 
5. Polymorphism selection and genotype characterization 
As systematically reviewed by our group, there are some observational data supporting 
the involvement of PTGS2 polymorphisms in gastrointestinal tumors development [13]. 
The PTGS2 polymorphisms included in this study (rs20417, rs689466 and rs5275) 
were selected based on: (1) previous evidence of association with colorectal tumor risk; 
(2) biological plausibility; and (3) minor allele frequency (MAF) of at least 15%.  
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HPGD polymorphisms where select by literature review of previous association with 
colorectal tumors onset (rs8752, rs2612656 and rs2555639).  
All polymorphisms were characterized through allelic discrimination (Real-Time 
Polymerase Chain Reaction) using validated TaqMan® SNP genotyping assays, with 
the exception of the polymorphism -765G>C (rs20417) which was custom designed 
(Applied Biosystems, Foster City, California USA) [Table I]. Reactions were performed 
on an Applied Biosystems 7300 Real Time PCR System (Applied Biosystems, Foster 
City, California USA) with a 6µl final volume mixture containing 2,5µl of the 2x TaqMan 
Genotyping Master Mix (Applied Biosystems, Foster City, California USA), 2,25 µL 
TaqMan SNP genotyping assays (Applied  Biosystems, Foster City, CA, USA) and 
20ng of genomic DNA. Thermal cycling conditions were: 95°C for 10 minutes, followed 
by 40 cycles that consisted of denaturation at 92°C for 15 seconds, annealing and 
primer extension at 60°C for 1 minute. The post-read was performed at 60ºC for 1 min. 
Allelic discrimination was performed by measuring end-point fluorescence using ABI 
PRISM® Sequence Detection System (Applied Biosystems, Foster City, California 
USA). 
 
Table I – Identification of the real-time genotyping assays, call rates and concordance rates for each SNP.  
Gene SNP ID (dbSNP) Assay ID 
 rs689466 C___2517145_20 
COX2 rs20417 Custom assay 
 rs5275 C___7550203_10 
 rs8752 C___8848783_10 
HPGD rs2612656 C___15909858_20 
 rs2555639 C___16038735_10 
 
Cases and controls were genotyped randomly and results were independently 
analyzed by two researchers. For quality control: (1) blank templates were included in 
each 96-well plate to ensure contamination-free results; (2) the genotype interpretation 
was performed by two researchers independently; (3) and ten percent of all samples 
were randomly selected and re-submitted to a new genetic characterization to confirm 
the genotypes. 
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6. Statistical analysis  
For genetic distribution analysis, the Hardy–Weinberg equilibrium was tested by the 
Pearson’s goodness-of-fit test to compare the observed versus the expected genotype 
frequencies.  
Data analysis was performed using the computer software IBM Statistical Package for 
Social Sciences-SPSS (IBM Corp., Armonk, New York, USA) for Macintosh (version 
19.0). Chi-square analysis was used to compare categorical variables, using a 5% level 
of significance. Odds ratio (OR) and its 95% confidence interval (CI) were calculated as 
a measure of the association between the genetic variants and the risk for the 
development of CRC. Homozygotes for the allele with the highest frequency were used 
as the reference group for each OR estimation. The potential confounding variables 
such as age, gender, body mass index (BMI), and smoking habits were addressed 
either by being included as covariates in the multivariate analysis and/or through data 
stratification. 
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1. Participants’ description 
In total, 254 cases of colorectal cancer and 544 cancer free controls were included in 
this study. The characteristics of the study population are presented in Table II. The 
median age of cases and controls were 57 (50-69) and 63 (50-78) years, respectively. 
Males were overrepresented in both cases and in the controls category (60.2% vs. 
64.2% in cases and controls, P=0.286) and over 75% of participants were overweight 
in either group (P=0.893). The majority of the participants had never smoked in both 
groups (61.8% in cases vs. 60.3% in controls, P=0.747). 
 
Table II – Description of participants 
 Cases 
(n=254) 
Controls 
(n=544) 
P value 
Demographics    
   Age (years)    
     Mean ± sd 63±7.22 58±4.89  
     Median(min-max) 63 (50-78) 57 (50-69) <0.001* 
   Sex, n (%)    
     Male 153 (60.2) 349 (64.2) 
0.286 
     Female 101 (39.8) 195 (35.8)  
Lifestyle behaviors
ª
    
   BMI    
     Mean (SD) 28±4.13 28±3.58 
0.764* 
     Median (min-max) 28 (20-43) 27 (20-41) 
     BMI category, n (%)
b
    
     <25 36 (23.4) 58 (24.0) 
0.893 
     ≥ 25 118 (76.6) 184 (76.0) 
     <30 114 (74.0) 184 (76.0) 
0.652 
     ≥30 40 (26) 58 (24) 
   Smoking status, n (%)    
     Never-smokers 97 (61.8) 240 (60.3) 
0.747 
     Ever-smokers* 60 (38.2) 158 (39.7) 
Tumor characteristics    
   Tumor location, n (%)    
     Rectum 132 (52.0)   
     Colon 121 (47.6)   
   Stage, n (%)    
     I-II 126 (49.6)   
     >II 115 (45.3)   
   Synchronous tumors, n (%)    
     Yes 14 (5.5)   
     No 224 (88.2)   
   Metachronous tumor, n (%)    
     Yes 3 (1.2)   
     No 103 (40.6)   
BMI, body mass index. 
ª
The numbers may not add up, as we were unable to gather this information for all participants, namely in the control group. 
b
Categorization based on the cutoff defined by WHO for overweight people [7] 
c
Smokers and ex-smokers were included 
*P value was estimated using the non-parametric Mann–Whitney test 
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2. Genotype frequencies and risk estimates for PTGS2 polymorphisms 
The distributions of each PTGS2 polymorphisms genotypes are shown in Table III. The 
genotypic distribution of all three SNPs in the control group was in agreement with the 
Hardy–Weinberg equilibrium principles (P≥0.05). 
Regarding the -1195A>G PTGS2 polymorphism, in the 252 analyzed cases, we 
observed that 58.7% were homozygous for A allele, 35.3% were heterozygous and 
6.0% were GG homozygous while in the control group the genotype frequencies were: 
68.3%, 28.3% and 3.4%, respectively. The GG and AG genotypes of the -1195A>G 
polymorphism were overrepresented in the group of cases leading to an increased risk 
for CRC, especially GG homozygous with 2-fold increased risk (OR 2.04; 95% CI: 1.00-
4.15; P=0.046). 
Regarding the -765G>C PTGS2 polymorphism, in the 249 analyzed cases, we 
observed that 73.9% were homozygous for G allele, 60.0% were heterozygous and 
2.1% were CC homozygous while in the control group the genotype frequencies were: 
67.7%, 29.5% and 2.8%, respectively. Although the results for the development of CRC 
were not statistically significant, we observed a protective role trend for CC 
homozygous (OR 0.62; 95% CI: 0.22-1.71; P=0.345).  
Regarding the 8473T>C PTGS2 polymorphism, in the 250 analyzed cases, we 
observed that 38.4% were heterozygous while in the control group the genotype 
frequency was 42.3%. The TT genotype has a frequency of 49.6% in cases versus 
48.9% in controls and the CC genotype was also more common in cases than in 
control group (12.0% vs. 8.7%, P=0.276). No significant differences in genotype 
distribution were noticed in this polymorphism. 
 
Table III – Genotype frequencies among cases and controls and univariate OR (95% CI) estimation on the role of 
PTGS2 polymorphisms in colorectal cancer onset 
 
Polymorphisms Cases 
n (%) 
Controls 
n (%) 
OR 95% CI P value HWE 
-1195A>G 
(rs689466) 
      
0.979 
AA 148 (58.7) 362 (68.3) 1.00 Reference -  
AG 89 (35.3) 150 (28.3) 1.45 1.05-2.01 0.024  
GG 15 (6.0) 18 (3.4) 2.04 1.00-4.15 0.046  
-765G>C  
(rs20417) 
      
0.972 
GG 184 (73.9) 362 (67.7) 1.00 Reference -  
GC 60 (24.1) 158 (29.5) 0.75 0.53-1.06 0.106  
CC 5 (2.0) 15 (2.8) 0.62 0.22-1.71 0.345  
8473T>C  
(rs5275) 
      
0.976 
TT 124 (49.6) 252 (48.9) 1.00 Reference -  
TC 96 (38.4) 218 (42.3) 0.90 0.65-1.24 0.518  
CC 30 (12.0) 45 (8.7) 1.33 0.80-2.20 0.276  
OR, odds ratio; CI, confidence interval; HWE, Hardy- Weinberg equilibrium
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3. Genotype frequencies and risk estimates for HPGD polymorphisms 
Table IV shows the results for the three analyzed SNPs in HPGD gene. All genotypic 
distributions in the control group were in agreement with the Hardy-Weinberg 
equilibrium principles (P≥0.05). 
Regarding the rs2555639T>C polymorphism genetic variation, in the 251 participants 
analyzed, the TT genotype had very similar frequencies in either groups (45.8% and 
46.1% in controls and cases, respectively). Similarly, the heterozygous TC as well as 
the homozygous CC, also presented similar distribution between cases and controls 
(42.2% and 12.0% vs. 43.5% and 10.4%, respectively). There was no significant 
difference in the genotype frequencies between the group of cases and controls. 
Regarding the rs2612656A>G HPGH polymorphism, in the 215 analyzed cases, we 
observed that 73.2% were homozygous for A allele, 21.1 % were heterozygous and 
5.7% were GG homozygous while in the control group the genotype frequencies were: 
65.4%, 38.4% and 4.2%, respectively. This polymorphism was significantly associated 
with a protective role for CRC (OR 0.62; 95% CI: 0.43-0.90, P= 0.011).  
For the rs8752T>C HPGD polymorphism, in the 209 analyzed cases, we observed that 
37.3% were homozygous for T allele, 45.6% were heterozygous and 17.1% were CC 
homozygous while in the control group the genotype frequencies were: 40.4%, 46.4% 
and 13.1%, respectively. Individuals carrying the CC genotype were associated with a 
nonsignificant 40% increase in risk of CRC (OR 1.41; 95% CI: 0.90-2.22; P=0.133). 
 
Table IV – Genotype frequencies among cases and controls and univariate OR (95% CI) estimation on the role of 
HPGD polymorphisms in colorectal cancer onset 
 
Polymorphisms Cases 
n (%) 
Controls 
n (%) 
OR 95% CI P value HWE 
rs2555639T>C      0.995 
TT 115 (45.8) 243 (46.1) 1.00 Reference -  
TC 106 (42.2) 229 (43.5) 0.98 0.71-1.35 0.892  
CC 30 (12.0) 55 (10.4) 1.15 0.70-1.90 0.575  
rs2612656A>G      0.899 
AA 167 (73.2) 329 (65.4) 1.00 Reference -  
AG 48 (21.1) 153 (38.4) 0.62 0.43-0.90 0.011  
GG 13 (5.7) 21 (4.2) 1.22 0.60-2.50 0.587  
rs8752T>C      0.996 
TT 94 (37.3) 216 (40.4) 1.00 Reference -  
TC 115 (45.6) 248 (46.4) 1.08 0.77-1.45 0.704  
CC 43 (17.1) 70 (13.1) 1.41 0.90-2.22 0.133  
OR, odds ratio; CI, confidence interval; HWE, Hardy- Weinberg equilibrium 
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4. Genotype-environment interactions 
Tables V and VI show the results for the influence of PTGS2 and HPGD 
polymorphisms in colorectal cancer stratified for age, sex, BMI and smoking status. 
Genotype association was tested for all heritability models and the most relevant will be 
presented. 
Upon a stratified analysis we observed that males carriers the -1195GG genotype had 
a 3-fold increased risk for CRC onset (OR 3.10; 95%CI: 1.22-7.88; P=0.013). The 
enhanced susceptibility was even more noticeable for individuals who ever-smoked 
prior to their diagnosis (OR 3.90; 95%CI: 1.17-12.96; P=0.019). 
A measurable interaction was detected between the rs2612656AG genotype and 
gender (OR 0.38; 95% CI: 0.19–0.76; P=0.005 in females) or smoking habits (OR 0.53; 
95% CI: 0.28–0.97; P=0.039 in never-smokers). More interestingly, the protective role 
for CRC seemed to be modulated by a high BMI (OR 0.39; 95% CI: 0.15–0.97; 
P=0.039 in individuals with BMI ≥30).  
The rs8752CC genotype was significantly associated with an increased risk in older 
individuals (OR 1.94; 95% CI: 1.04-3.61; P=0.035 in individuals over age 59). 
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Table V – Odds Ratio (95% CI) for the influence of PTGS2 polymorphisms in colorectal cancer stratified for age, sex, BMI and smoking status 
 -1195A>G (GG vs. AA) -765G>C (CC vs. GG) 8473T>C (CC vs. TT) 
Stratification N OR 95% CI P value N OR 95% CI P value N OR 95% CI P value 
Age (years)ª             
<59 271 1.66 0.50-5.50 0.297 268 0.36 0.05-2.83 0.275 214 1.74 0.78-3.85 0.172 
≥59 270 2.18 0.85-5.62 0.099 295 0.95 0.25-3.60 0.605 235 1.12 0.57-2.22 0.738 
Sex             
Male 341 3.10 1.22-7.88 0.013 357 0.67 0.18-2.51 0.398 295 1.21 0.64-2.28 0.556 
Female 202 1.10 0.36-3.43 0.866 210 0.55 0.11-2.70 0.361 157 1.66 0.69-3.98 0.252 
 BMI (kg/m
2
)             
<25 68 1.75 0.11-29.27 0.604 61 1.38 0.18-10.46 0.574 53 1.24 0.30-5.11 0.516 
≥25 202 2.12 0.63-7.21 0.219 212 0.37 0.04-3.40 0.341 158 1.11 0.47-2.64 0.806 
<30 200 3.19 0.90-11-28 0.060 194 1.20 0.26-5.60 0.553 160 0.96 0.40-2.26 0.321 
≥ 30 70 0.62 0.51-0.75 0.392 74 0.54 0.44-0.67 0.304 51 1.84 0.43-7.85 0.321 
Smoking status             
Never-smokers 227 0.59 0.12-2.83 0.302 238 0.39 0.05-3.31 0.338 190 1.30 0.52-3.25 0.568 
Ever-smokers
b
 159 3.90 1.17-12.96 0.019 151 1.01 0.20-5.78 0.612 119 1.51 0.57-4.00 0.400 
OR, odds ratio; CI, confidence interval; 
a
Categorization defined by the overall median age; 
b 
Includes ever-smokers and ex-smoker 
Table VI – Odds Ratio (95% CI) for the influence of HPGD polymorphisms in colorectal cancer stratified for age, sex, BMI and smoking status 
OR, odds ratio; CI, confidence interval; 
a
Categorization defined by the overall median age; 
b 
Includes ever-smokers and ex-smokers 
 rs2555639T>C (CC vs. TT) rs2612656A>G (AG vs. AA) rs8752T>C (CC vs. TT) 
Stratification N OR 95% CI P value N OR 95% CI P value N OR 95% CI P value 
Age (years)ª             
<59 212 1.27 0.53-3.05 0.591 346 0.63 0.36-1.13 0.119 200 1.10 0.52-2.23 0.816 
≥59 230 0.94 0.50-1.76 0.847 347 0.69 0.41-1.15 0.149 220 1.94 1.04-3.61 0.035 
Sex             
Male 281 0.86 0.44-1.65 0.642 137 0.79 0.50-1.23 0.289 268 1.27 0.71-2.28 0.416 
Female 162 1.79 0.82-3.91 0.145 242 0.38 0.19-0.76 0.005 155 1.63 0.80-3.34 0.178 
 BMI (kg/m
2
)             
<25 43 0.67 0.17-2.67 0.413 84 0.87 0.31-2.47 0.793 48 1.22 0.27-5.59 0.548 
≥25 171 1.73 0.79-3.96 0.119 85 0.67 039-1.15 0.146 163 1.26 0.63-2.51 0.515 
<30 152 1.89 0.48-7.40 0.356 268 0.88 0.51-1.52 0.640 157 1.15 0.55-2.40 0.714 
≥ 30 62 1.89 0.48-7.40 0.356 85 0.39 0.15-1.02 0.051 54 1.33 0.40-4.40 0.636 
Smoking status             
Never-smokers 181 1.66 0.76-3.61 0.203 296 0.53 0.28-0.97 0.039 192 1.27 0.62-2.60 0.506 
Ever-smokers
b
 117 1.23 0.45-3.32 0.685 199 1.29 0.67-2.49 0.448 111 1.45 0.58-3.60 0.423 
2
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CRC incidence and mortality rate have decreased during the past few decades. 
Nevertheless it is still the fourth cause of cancer death worldwide and a major 
worldwide health problem especially in developed countries [1,145]. It has been shown 
that environmental and genetic factors have a substantial role in colorectal 
carcinogenesis and current research points that the identification of specific tumor 
promoter or suppressor genes will provide new targets for prevention, diagnosis and 
cancer therapies which may help to stop CRC burden and mortality [83,92]. 
Several studies have been confirming that inflammation plays a key role in the 
development of cancer, especially in CRC [51,52,56,107]. Inflammation is regulated by 
several cellular mechanisms that are used to control cellular abnormalities assumed as 
crucial for cancer prevention. In the inflammation process, PTGS2 is a significant 
marker and its association with cancer is being widely studied [92,93,95]. Moreover, 
HPGD is considered an important regulator of inflammation and some studies point its 
importance in cancer [67,68]. 
COX-2 derived PGE2 is produced during the course of inflammation and is presence in 
tumor environment seems to favor tumor progression [64]. The steady-state level of 
PGE-2 is maintained in the tumor microenvironment by a balance between 
biosynthesis (by COX-2) and degradation (by 15-PGDH). Enhanced expression of 
COX-2 has been observed in many cancers, including CRC [146] and it is known that 
HPGD expression is lost in human colon cancer cells [69]. These findings indicate that 
genetic variants involved in the PG synthesis pathway may modulate the risk for CRC. 
 
Firstly, it is important to characterize the limitations of this study to avoid 
misunderstandings of data. In this study we have included a total of 254 patients and 
544 controls, nevertheless we were not able to obtain some clinical information from 
patients (such as weight, length and smoking habits). Therefore the analysis of BMI 
and smoking status may be biased due to the lack of some data and might explain the 
low statistical power found in some groups. Secondly, although we imposed the same 
age-restriction criteria in both groups, we noticed that CRC patients were significantly 
older than controls, which had impact on the stratified analysis. 
Another limitation was the fact that not all patients were able to provide a blood sample, 
and DNA was extracted from FFPE. FFPE is the standard method for long-term 
preservation of clinical specimens and the usual technique for preserving specimens in 
hospital pathology departments. In recent years, due to the worldwide abundance of 
these samples, an increasing number of studies have been conducted using FFPE 
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tissue for nucleic acid extraction. However, the fixation process and storage of FFPE 
samples normally leads to nucleic acid degradation resulting in poor performance in 
genotyping studies. To overcome this we characterized all the SNPs using Real Time 
PCR that produce smaller size amplicons increasing the chance to detect a specific 
locus. We also validated the use of FFPE samples in this study by successfully 
demonstrating good concordance between genotypes obtained from DNA extracted 
from peripheral blood and FFPE samples. 
 
Role of polymorphisms in PTGS2 gene on CRC onset 
A number of associations between several SNPs in PTGS2 and CRC have been 
reported [92,101,107,112]. Previously, in a preliminary study from our group it was 
reported that individuals’ carriers of the -1195G allele were at an increased risk for 
CRC development [102]. In fact, the present study supports that first observation and 
results showed an over representation of AG and GG genotypes in the group of cases 
leading to an increased risk for CRC, especially GG homozygous with 2-fold increased 
risk. Moreover, a published study involving FAP patients also reported an increased 
risk association between -1195GG genotype and CRC onset [100]. However, these 
associations have raised some controversy. According to Zhang et al. [96] the -1195AA 
genotype was associated with a significantly higher risk for esophageal cancer. In 
addition, it was reported in several studies in Asiatic populations the association of the 
AA genotype with higher genetic predisposition for the development of gastric and CRC 
[97-99]. In vitro studies were developed to clarify these conflicting associations and 
while it was shown that the presence of -1195A allele creates a c-MYB-binding site, 
resulting in higher transcriptional activity of the PTGS2 in esophageal cancer cells [96], 
Pereira et al. [97] using colon cancer cell lines reported that the -1195A to G 
substitution also creates an E-box motif which may lead to increased PTGS2 
transcription. Same results were observed in human hepatoma cell lines [147]. These 
two studies contribute for the support of our results corroborating the higher 
susceptibility for CRC that we found in individuals with GG genotype. Moreover, when 
we assessed possible gene–environment interactions, we observed a positive 
association between -1195GG genotype and CRC in males and in ever-smokers. 
Several studies already reported that CRC occurs earlier in smokers [148-151] and a 
meta-analysis study revealed that cigarette smoking doubles the risk of developing 
adenomatous polyps, known precursors of CRC [152]. Several theories regarding the 
smoke-induced cancer were developed and some authors suggest that one of the 
pathways could be due to COX-2 overexpression leading to a sustained inflammatory 
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activity [153,154]. Nevertheless however the pathogenesis of smoking related CRC is 
still lacking more studies and evidences. 
Regarding -765G>C polymorphism we observed a trend for a protective role in 
individuals carrying the CC genotype, however these results were not statistically 
significant. It has been described that -765C allele has significantly lower promoter 
activity when compared with the -765G allele and therefore is associated with COX-2 
under-expression [103]. Furthermore, in a previous study, the -765CC genotype 
showed a protective role for colorectal adenomas and hyperplastic polyps [111]. In 
addition, this genotype was also associated with a reduced risk for developing Crohn's 
disease in a Dutch population [155]. However, a recent meta-analysis found a 
significant association between the -765CC genotype and CRC risk in Asiatic 
populations [156]. The dual and antagonistic results observed with this polymorphism 
might have a biological interpretation, as the presence of allele C in PTGS2 promoter 
region eliminates the recognition binding site for the Sp1 positive transcription factor 
leading to a 30% reduction of promoter activity in vitro [103] but it also creates a E2F 
homology binding site region that could explain the overexpression and increased risk 
[95,98]. Studies also suggested that ethnic and environment differences may influence 
the function of -765G>C polymorphism, therefore studies that investigate the 
association of specific life-style conditions with this polymorphism in patients with CRC 
may help to elucidate the contradictory results obtained with this polymorphism.  
The 8473T>C PTGS2 polymorphism is located within the functional region of the 3’-
UTR of PTGS2 which contains multiple elements that control mRNA stability and 
translation efficiency [113-115]. The functional importance of 8473T>C PTGS2 
polymorphism was recently investigated and an in vitro study showed that the presence 
of the variant C disrupted microRNA-mRNA interaction allowing COX-2 overexpression 
in CRC cells [157]. A recent metaanalysis has shown that the 8473C allele has been 
associated with a 1.25-fold increased susceptibility for colorectal adenoma and in 
contradiction with a protective role for gastric cancer [92]. However, there are some 
studies that establish no association between this polymorphism and CRC cancer 
[102,121,122]. In our study, the statistical analysis revealed no association between 
any of the genotypes of this polymorphism and CRC risk, which is in agreement with 
previous published studies [102,121,122]. So, this polymorphism may be a genetic risk 
factor in some populations but not in our. 
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Role of polymorphisms in HPGD gene on CRC onset 
Regarding to HPGD, only more recently it has aroused great interest with few studies 
reporting an influence of HPGD SNPs in CRC [139-141]. To the best of our knowledge, 
this is the first study to evaluate the association between HPGD polymorphisms and 
CRC susceptibility in a Portuguese population. 
Statistically analysis revealed that only the rs2612656AG genotype is significantly 
associated with protection for CRC development. These results are contrary to those 
obtained by Hoef et al. [141] where this variant was associated with higher CRC risk. 
First it is important to refer that differences in genetic ancestry may explain these 
inconsistent results since our samples were exclusively from the north region of 
Portugal whereas Hoef et al. [141] analyzed cases from ten European countries with 
different rates of CRC incidence. The diversity in genetic and environment 
backgrounds that is expected to find in the studied populations may also clarify these 
findings. When we assessed possible gene–environment interactions, a protection for 
CRC was observed for females and never-smokers carriers of the heterozygous 
genotype (AG). Smoking is associated with a higher risk of several types of cancer 
including CRC [148-152]. Recent metaanalyses suggest that current or former smokers 
had almost 20% increased risk of CRC when compared with never-smokers [158,159]. 
Moreover, it is known that men have a higher prevalence of colon polyps and tumors 
than women [160]. However, females smokers were found to be more susceptible to 
colon cancer than male smokers among Norwegians individuals [161]. These findings 
seem to suggest that other life-style factors, besides smoking, may interfere in the 
development of CRC. More interesting, our results demonstrated that heterozygous 
(AG) individuals with a BMI ≥ 30, despite borderline significance, seem to have a 
decreased risk for CRC. These results were unexpected since there is clear evidence 
that people who are obese (with BMI ≥ 30 kg/m2) have an increased risk for developing 
CRC [162,163]. Since the obese state leads to production of some molecules that are 
known to be involved in inflammation, such as prostaglandins, it is possible that some 
common mechanism between obesity and CRC exists [164,165]. Studies identifying 
genetic and biological determinants of obesity and its interactions with HPGD may help 
elucidate these results. 
Regarding to rs8752 polymorphism, we found a nonsignificant 40% increased risk with 
the CC genotype that reaches significance level when we assessed possible gene-
environment interactions. We observed an almost 2-fold increased risk in older 
individuals. Previous studies assessing the influence of rs8752 polymorphism on CRC 
risk reported opposite results: one found this polymorphism to be associated with CRC 
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risk [141] while other reported a protective role for CRC [139]. These variable findings 
and the increase risk that we observed in older individuals may be due to gene-gene 
and gene-environment interactions, which support the idea that CRC is a multifactorial 
disease. 
Moreover and although a recent study has shown an association of rs2555639 T allele 
with increased risk of colorectal cancer [140], we were not able to replicate this result in 
our study.  
As already mentioned, the heterogeneity observed among epidemiological studies 
might be explained by population stratification, also involving differences in genetic 
lineage, and by different environmental backgrounds, thus reinforcing the idea that it is 
important to evaluate the influence of SNPs in CRC in independent populations. 
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With this study we attempted to replicate genetic associations between six 
polymorphisms (rs689466, rs20417 and rs5275 in PTGS2 and rs8752, rs2612656 and 
rs2555639 in HPGD) and CRC risk. All this polymorphisms were previously reported to 
have some association with CRC. Nevertheless, this is the first study to combine all 
genetic inflammation in one study. 
Regarding to PTGS2, we found -1195GG genotype to be significantly associated with a 
increased CRC risk especially both among males and among ever-smokers. We also 
observed a protective role trend for individuals carrying the -765CC genotype.  
Regarding to HPGD, we found rs2612656AG genotype to be significantly associated 
with a decreased risk especially both among females and never-smokers. We also 
observed that individuals with a BMI ≥ 30 presenting this genotype also seem to have a 
decreased risk for CRC. Regarding to rs8752T>C polymorphism, we found a 
nonsignificant 40% increased risk with the CC genotype and an almost 2-fold 
significant increased risk in older individuals carrying the same genotype. 
In the future it will be interesting to characterize functionally the interaction between -
1195A>G polymorphism and smoke-induced colorectal carcinogenesis to evaluate if 
this association may represent a risk model for CRC development. Also it would be 
appealing to examine a possible interaction between these polymorphisms and 
NSAIDs use that could allow us to define a pharmacogenomic profile. Furthermore, 
expression studies of rs8752T>C and rs2612656A>G HPGD polymorphisms may help 
elucidate their impact in CR carcinogenesis observed in our case-control study. 
Therefore, the analysis of potentially functional SNPs in candidate genes might allow 
the characterization of sub-groups of individuals at higher risk for cancer development. 
These groups could have a more premature diagnosis and benefit from personalized 
chemopreventive strategies. Our data underlines the oncogenic importance of the PG 
pathway and its influence in the development of CRC cancer.  
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